The Swiss biopharmaceutical company Light Chain Bioscience has developed a novel and unique class of human, bispecific antibodies dubbed κλ bodies, so-called because they combine a κ light ...

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Although fewer antibody fragments have entered the clinic than full-length monoclonal antibodies, proof-of-concept studies for these therapeutics remain the main hurdle. Tufts Center for the Study ...

Boston: Alloy Therapeutics Inc., a biotechnology ecosystem company has announced its latest strategic collaboration with ...

An antibody molecule consists of two heavy chains (approximately 50 kDa each) and two light chains (approximately 25 kDa each). These chains are interconnected by disulfide bonds, resulting in a ...

Alloy Therapeutics Inc., a biotechnology ecosystem company, has joined forces with Pfizer Inc., to develop a new platform ...

The year 2015 marked the inception of Sanyou Bio's technological journey, laying the foundation for its core technology platform. The R&D team devoted itself to the development of display vectors, ...

after a few immunizations the immune system begins to produce antibodies against immune complexes already bound to the viral protein alone. They don't yet know whether this chain reaction ...

The heavy and light chains of that fully human anti-human eosinophil mAb were delivered via an adeno-associated virus (AAV)-based gene therapy to immunodeficient mice, where they suppressed levels ...